glp-1 obesity drugs pipeline Harnessing Receptor Agonists for Treatment: Prospects and Obstacles on the Horizon Anti-Obesity Drugs – Pharma Companies

Tirzepatide: a novel, first-in-class, dual GIP/GLP-1 receptor agonist

DPP4 inhibitors primarily target the postprandial plasma glucose (PPG), whereas, GLP1 receptor agonists target fasting plasma glucose (FPG) as well as PPG

Endogenous GLP-1 has a short half-life since it is in 1-2 minutes degraded by the enzyme dipeptidyl peptidase-4 (DPP-4)

Human trials are ongoing, but even modest effects in opioid use disorder could be clinically meaningful given the favorable safety profile of GLP-1 drugs compared with existing treatments

10.2337/db11-1109 6 HathawayJ

[DOI] [PMC free article] [PubMed] [Google Scholar] 39.Jastreboff A.M., Kaplan L.M., Fras J.P., Wu Q., Du Y., Gurbuz S., Coskun T., Haupt A., Milicevic Z., Hartman M.L